Robert Glatter, MD, an emergency physician at Lenox Hill Hospital in New York City and assistant professor at Zucker School of Medicine, told Healthline that these findings support the idea that some patients may have partial biologic resistance to incretin-based therapies. He added that genetics explains only part of the treatment differences and that routine pharmacogenomic screening is not yet ready for widespread clinical use. The same article noted that this PAM research looked at bloodsugar control, not weight loss, and GLP1 drugs are typically prescribed at higher doses for obesity than for diabetes
Microdosing GLP-1s, like Ozempic or Wegovy, has exploded in popularity over the past year with some TikTok creators saying it has completely changed their lives. Some are microdosing as a way to maintain weight, while others are using it as a cost-cutting method
[DOI] [PMC free article] [PubMed] [Google Scholar] 178.Amiri S
All-cause and cardiovascular mortality hazard ratios (HRs) were calculated from studies with at least 1,000 participants
Ted The doctor was very informative of all aspects of the medication that I am now taking
